Disinfectants In Interventional Practices
PURPOSE OF REVIEW: This review aims to provide relevant, aggregate information about a variety of disinfectants and antiseptics, along with potential utility and limitations. While not exhaustive, this review's goal is to add to the body of literature available on this topic and give interventional providers and practitioners an additional resource to consider when performing procedures.
RECENT FINDINGS: In the current SARS-CoV2 epidemiological environment, infection control and costs associated with healthcare-associated infections (HAIs) are of paramount importance. Even before the onset of SARS-CoV2, HAIs affected nearly 2million patients a year in the USA and resulted in nearly 90,000 deaths, all of which resulted in a cost to hospitals ranging from US$28 billion to 45 billion. The onset SARS-CoV2, though not spread by an airborne route, has heightened infection control protocols in hospitals and, as such, cast a renewed focus on disinfectants and their utility across different settings and organisms. The aim of this review is to provide a comprehensive overview of disinfectants used in the inpatient setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current pain and headache reports - 25(2021), 4 vom: 11. März, Seite 21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aranke, Mayank [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.11.2021 Date Revised 18.02.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11916-021-00938-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322510724 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322510724 | ||
| 003 | DE-627 | ||
| 005 | 20231225182207.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11916-021-00938-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322510724 | ||
| 035 | |a (NLM)33693989 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aranke, Mayank |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Disinfectants In Interventional Practices |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2021 | ||
| 500 | |a Date Revised 18.02.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE OF REVIEW: This review aims to provide relevant, aggregate information about a variety of disinfectants and antiseptics, along with potential utility and limitations. While not exhaustive, this review's goal is to add to the body of literature available on this topic and give interventional providers and practitioners an additional resource to consider when performing procedures | ||
| 520 | |a RECENT FINDINGS: In the current SARS-CoV2 epidemiological environment, infection control and costs associated with healthcare-associated infections (HAIs) are of paramount importance. Even before the onset of SARS-CoV2, HAIs affected nearly 2million patients a year in the USA and resulted in nearly 90,000 deaths, all of which resulted in a cost to hospitals ranging from US$28 billion to 45 billion. The onset SARS-CoV2, though not spread by an airborne route, has heightened infection control protocols in hospitals and, as such, cast a renewed focus on disinfectants and their utility across different settings and organisms. The aim of this review is to provide a comprehensive overview of disinfectants used in the inpatient setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Disinfectants | |
| 650 | 4 | |a Healthcare-associated infections | |
| 650 | 4 | |a Inpatient | |
| 650 | 4 | |a Interventional practices | |
| 650 | 4 | |a SARS-COV2 | |
| 650 | 7 | |a Chlorine Compounds |2 NLM | |
| 650 | 7 | |a Disinfectants |2 NLM | |
| 650 | 7 | |a Iodophors |2 NLM | |
| 650 | 7 | |a Oxides |2 NLM | |
| 650 | 7 | |a Quaternary Ammonium Compounds |2 NLM | |
| 650 | 7 | |a Triazines |2 NLM | |
| 650 | 7 | |a superoxidized water |2 NLM | |
| 650 | 7 | |a Formaldehyde |2 NLM | |
| 650 | 7 | |a 1HG84L3525 |2 NLM | |
| 650 | 7 | |a Phenol |2 NLM | |
| 650 | 7 | |a 339NCG44TV |2 NLM | |
| 650 | 7 | |a Ethanol |2 NLM | |
| 650 | 7 | |a 3K9958V90M |2 NLM | |
| 650 | 7 | |a chlorine dioxide |2 NLM | |
| 650 | 7 | |a 8061YMS4RM |2 NLM | |
| 650 | 7 | |a Povidone-Iodine |2 NLM | |
| 650 | 7 | |a 85H0HZU99M |2 NLM | |
| 650 | 7 | |a Hydrogen Peroxide |2 NLM | |
| 650 | 7 | |a BBX060AN9V |2 NLM | |
| 650 | 7 | |a Sodium Hypochlorite |2 NLM | |
| 650 | 7 | |a DY38VHM5OD |2 NLM | |
| 650 | 7 | |a Peracetic Acid |2 NLM | |
| 650 | 7 | |a I6KPI2E1HD |2 NLM | |
| 650 | 7 | |a troclosene |2 NLM | |
| 650 | 7 | |a PHR838Y52L |2 NLM | |
| 650 | 7 | |a Glutaral |2 NLM | |
| 650 | 7 | |a T3C89M417N |2 NLM | |
| 700 | 1 | |a Moheimani, Roya |e verfasserin |4 aut | |
| 700 | 1 | |a Phuphanich, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Ngo, Anh L |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Herman, Jared |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pain and headache reports |d 2001 |g 25(2021), 4 vom: 11. März, Seite 21 |w (DE-627)NLM111627923 |x 1534-3081 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2021 |g number:4 |g day:11 |g month:03 |g pages:21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11916-021-00938-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2021 |e 4 |b 11 |c 03 |h 21 | ||